MCL Literature Feed

A preclinical multi-modal profiling platform integrating genomics, in vitro drug screening, and PDX models identified personalized therapies for BTKi-relapsed/refractory MCL, guiding treatment beyond single gene alterations.

Pirtobrutinib-tolerant MCL persister cells survive via a reversible TCA cycle metabolic switch, presenting a novel metabolic vulnerability to target and prevent drug resistance.

Blastoid or pleomorphic morphology in mantle cell lymphoma is associated with increased primary and acquired resistance to BTK inhibitors, identifying a high-risk population requiring alternative therapeutic strategies.

Optical Genome Mapping identified a rare IGL::CCND1 translocation in a CD23-positive case, revising a CLL diagnosis to MCL and demonstrating OGM's utility for detecting atypical presentations.

This report identifies KMT2A rearrangement as a rare genetic driver in MCL, defining a distinct subtype often associated with aggressive features like blastoid morphology and poor prognosis.

This review explains how tumor microenvironment crosstalk with B-cell receptor signaling promotes MCL survival and BTKi resistance, underscoring the need to target these interactions for improved therapies.

Integrating genomics and spatial proteomics defines three prognostic MCL subtypes, revealing high-risk TP53-mutated tumors are immune-infiltrated yet exhausted, highlighting potential therapeutic vulnerabilities.

A patient-derived organoid model from prostate-metastatic MCL predicted sensitivity to gemcitabine but resistance to rituximab/oxaliplatin, offering a new platform for personalized therapy selection in heterogeneous disease.

This review highlights the diagnostic challenge of distinguishing mantle cell lymphoma with plasmacytic differentiation from multiple myeloma, particularly the CCND1-translocated subtype, emphasizing the need for careful molecular workup.

CT-based radiomics combined with machine learning accurately differentiates MCL from other lymphomas non-invasively, potentially improving diagnostic precision and guiding biopsies in treatment-naïve patients.

This case report of MCL with atypical cytology (abundant, irregular cytoplasm) highlights the crucial role of flow cytometry in achieving an accurate diagnosis when morphology is misleading.

The novel oral CDK9 inhibitor YX0798 demonstrates high selectivity and potent preclinical activity in MCL by downregulating MYC/MCL-1, offering a potential strategy to overcome therapeutic resistance.

This review details the oncogenic role of the FoxO1 transcription factor in MCL, highlighting its potential as a novel therapeutic target with specific preclinical inhibitors under investigation.

This Danish nationwide study confirms blastoid morphology, high Ki67, and high CNS-IPI as key risk factors for secondary CNS lymphoma, supporting consideration of upfront CNS screening in high-risk patients.

NCCN guidelines now highlight BTK inhibitor-based regimens as effective options for high-risk, TP53-mutated classical mantle cell lymphoma, formalizing a key strategy for this difficult-to-treat population.

Light-chain-restricted hematogones in bone marrow can mimic MCL on flow cytometry, creating a significant diagnostic pitfall that could lead to misdiagnosis or incorrect staging assessments.

In newly diagnosed MCL, ATM deletion predicts shorter progression-free survival in TP53 wild-type patients, whereas ATM mutation may indicate a better prognosis, highlighting their distinct prognostic roles.

High-throughput sequencing accurately identifies IGHV somatic hypermutation status, a key prognostic biomarker in MCL, even in complex, multi-clonal samples, improving risk stratification and MRD tracking.

ctDNA sequencing in relapsed/refractory MCL identifies SMARCA4 and TP53 mutations as response predictors and offers more sensitive MRD monitoring than qPCR, improving non-invasive risk stratification.

Comprehensive cfDNA analysis non-invasively tracks MCL disease burden and detects high-risk mutations, offering a powerful liquid biopsy tool for monitoring and risk stratification.

BRG1-driven suppression of ferroptosis is a key mechanism of BTKi resistance in MCL, and pharmacologic BRG1 inhibition restores BTKi sensitivity, suggesting a new combination therapy.

Cyclin D1 overexpression induces replication stress and a dependency on POLQ-mediated DNA repair, identifying POLQ inhibition as a novel, targeted therapeutic strategy for mantle cell lymphoma.

Nodal MCL with leukemic presentation is a high-risk subtype characterized by SOX11-negativity, increased TP53 alterations, and inferior overall survival, requiring distinct clinical consideration.

Digital analysis of p53 immunohistochemistry establishes specific cut-offs (e.g., >50% for 2+/3+ nuclei) that reliably identify TP53 mutations and predict worse survival, improving rapid risk stratification.

A rare case of composite CLL/MCL highlights diagnostic challenges from overlapping immunophenotypes, reinforcing the critical need for molecular and cytogenetic studies like FISH for t(11;14) for definitive diagnosis.

In elderly, frontline MCL, this SHINE secondary analysis shows achieving a complete response is critical for long-term PFS, and adding ibrutinib to BR significantly increases CR rates.

Retrospective data show B symptoms and CBV conditioning negatively impact survival post-ASCT in MCL, supporting BeEAM conditioning and risk-adapted strategies for consolidation.

Serum beta-2 microglobulin is a critical prognostic biomarker in lymphoma, including MCL, where it reflects tumor burden and is a key component of the MIPI risk score.

This case report describes a rare intrasinusoidal presentation of pleomorphic MCL, highlighting a critical diagnostic pitfall that can mimic intravascular large B-cell lymphoma.

High NSD2 expression and specific mutations correlate with aggressive MCL variants, poorer treatment response, and inferior survival, establishing NSD2 as a key prognostic biomarker and potential therapeutic target.